Summary. Iloperidone is an atypical antipsychotic that recently received marketing approval from the Food and Drug Administration for the acute treatment of schizophrenia. Iloperidone is a pure ...

Medically reviewed by Lindsay Cook, PharmD According to the National Institute of Mental Health (NIMH), more than one in five ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in September, some researchers have proclaimed a new era for psychiatric ...

A person has treatment-resistant schizophrenia if they try two or more schizophrenia drugs at the right dose and do not see any improvement in symptoms. A 2020 study estimates that 34% of people ...

Medically reviewed by Steven Gans, MDDisorganized schizophrenia is characterized by speech, emotional expressions, thoughts, and actions that are "disorganized" or not in tune with what is expected or ...

Schizophrenia is a serious mental illness that requires treatment with medication to lessen symptoms. But even if your symptoms go away, you'll need to stay on treatment to avoid a relapse.

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent $9 billion ...

Although antipsychotics were developed to treat schizophrenia, newer ones are sometimes used to treat depression that has not ...

Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial. Intra-Cellular's schizophrenia drug meets main goal in late ...

Nov 11 (Reuters) - AbbVie (ABBV.N), opens new tab shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie (ABBV) said that its Phase 2 trial ...